vs
Evolent Health, Inc.（EVH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Evolent Health, Inc.的1.6倍（$772.1M vs $468.7M），Revvity净利率更高（12.7% vs -91.6%，领先104.3%），Revvity同比增速更快（5.9% vs -27.5%），过去两年Revvity的营收复合增速更高（9.0% vs -14.4%）
马奎尔健康是一家美国营利性医疗管理企业，目前为森特里奇旗下子公司，核心服务对象为特殊群体，业务聚焦医疗领域多个细分赛道。客户群体涵盖健康保险计划、其他管理式医疗机构、企业、工会、各类军事与政府机构以及第三方管理机构，2021年位列财富美国500强第390名。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EVH vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$468.7M
营收增速更快
RVTY
高出33.4%
-27.5%
净利率更高
RVTY
高出104.3%
-91.6%
两年增速更快
RVTY
近两年复合增速
-14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $468.7M | $772.1M |
| 净利润 | $-429.1M | $98.4M |
| 毛利率 | 20.7% | — |
| 营业利润率 | -87.1% | 14.5% |
| 净利率 | -91.6% | 12.7% |
| 营收同比 | -27.5% | 5.9% |
| 净利润同比 | -1782.0% | 3.9% |
| 每股收益（稀释后） | $-3.76 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVHRVTY
| Q4 25 | $468.7M | $772.1M | ||
| Q3 25 | $479.5M | $698.9M | ||
| Q2 25 | $444.3M | $720.3M | ||
| Q1 25 | $483.6M | $664.8M | ||
| Q4 24 | $646.5M | $729.4M | ||
| Q3 24 | $621.4M | $684.0M | ||
| Q2 24 | $647.1M | $691.7M | ||
| Q1 24 | $639.7M | $649.9M |
净利润EVHRVTY
| Q4 25 | $-429.1M | $98.4M | ||
| Q3 25 | $-20.9M | $46.7M | ||
| Q2 25 | $-19.9M | $53.9M | ||
| Q1 25 | $-64.6M | $42.2M | ||
| Q4 24 | $-22.8M | $94.6M | ||
| Q3 24 | $-23.1M | $94.4M | ||
| Q2 24 | $1.6M | $55.4M | ||
| Q1 24 | $-17.3M | $26.0M |
毛利率EVHRVTY
| Q4 25 | 20.7% | — | ||
| Q3 25 | 20.8% | 53.6% | ||
| Q2 25 | 22.6% | 54.5% | ||
| Q1 25 | 21.2% | 56.5% | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 13.0% | 56.3% | ||
| Q2 24 | 16.5% | 55.7% | ||
| Q1 24 | 16.3% | 54.6% |
营业利润率EVHRVTY
| Q4 25 | -87.1% | 14.5% | ||
| Q3 25 | 0.2% | 11.7% | ||
| Q2 25 | -0.3% | 12.6% | ||
| Q1 25 | -0.3% | 10.9% | ||
| Q4 24 | -2.9% | 16.3% | ||
| Q3 24 | -2.6% | 14.3% | ||
| Q2 24 | 1.2% | 12.4% | ||
| Q1 24 | -2.1% | 6.8% |
净利率EVHRVTY
| Q4 25 | -91.6% | 12.7% | ||
| Q3 25 | -4.4% | 6.7% | ||
| Q2 25 | -4.5% | 7.5% | ||
| Q1 25 | -13.4% | 6.4% | ||
| Q4 24 | -3.5% | 13.0% | ||
| Q3 24 | -3.7% | 13.8% | ||
| Q2 24 | 0.2% | 8.0% | ||
| Q1 24 | -2.7% | 4.0% |
每股收益（稀释后）EVHRVTY
| Q4 25 | $-3.76 | $0.86 | ||
| Q3 25 | $-0.24 | $0.40 | ||
| Q2 25 | $-0.44 | $0.46 | ||
| Q1 25 | $-0.63 | $0.35 | ||
| Q4 24 | $-0.26 | $0.77 | ||
| Q3 24 | $-0.27 | $0.77 | ||
| Q2 24 | $-0.06 | $0.45 | ||
| Q1 24 | $-0.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $415.2M | $7.3B |
| 总资产 | $1.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EVHRVTY
| Q4 25 | $151.9M | $919.9M | ||
| Q3 25 | $116.7M | $931.4M | ||
| Q2 25 | $151.0M | $991.8M | ||
| Q1 25 | $246.5M | $1.1B | ||
| Q4 24 | $104.2M | $1.2B | ||
| Q3 24 | $96.6M | $1.2B | ||
| Q2 24 | $101.3M | $2.0B | ||
| Q1 24 | $165.1M | $1.7B |
股东权益EVHRVTY
| Q4 25 | $415.2M | $7.3B | ||
| Q3 25 | $842.2M | $7.4B | ||
| Q2 25 | $896.0M | $7.6B | ||
| Q1 25 | $935.5M | $7.6B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $1.0B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产EVHRVTY
| Q4 25 | $1.9B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.5B | $12.4B | ||
| Q3 24 | $2.5B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B | ||
| Q1 24 | $2.6B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流EVHRVTY
| Q4 25 | $48.8M | $182.0M | ||
| Q3 25 | $15.8M | $138.5M | ||
| Q2 25 | $-30.3M | $134.3M | ||
| Q1 25 | $4.6M | $128.2M | ||
| Q4 24 | $-26.2M | $174.2M | ||
| Q3 24 | $18.7M | $147.9M | ||
| Q2 24 | $21.4M | $158.6M | ||
| Q1 24 | $4.9M | $147.6M |
自由现金流EVHRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率EVHRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度EVHRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率EVHRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 13.42× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVH
| Commercial And Other Customers | $147.9M | 32% |
| Medicare Customers | $111.2M | 24% |
| Specialty Technology And Services Suite | $95.7M | 20% |
| Administrative Service | $55.8M | 12% |
| Cases | $47.7M | 10% |
| Related Party | $4.5M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
